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Purpose: Circumferential resection margin (CRM) involvement is a well-known 
predictor for poor prognosis in rectal cancer. However, the significance is contro-
versial in some studies. Accordingly, this study attempted to examine the prognos-
tic impact of CRM involvement in stage III rectal cancer. Materials and Meth-
ods: Between January 1990 and December 2007, a total of 449 patients who 
underwent curative resection followed by complete adjuvant chemoradiotherapy 
for stage III rectal cancer located within 12 cm from the anal verge were selected. 
Patients were divided into a CRM-positive group (n=79, 17.6%) and a CRM-neg-
ative group (n=370, 82.4%). Results: With a median follow-up of 56.6 months, re-
current disease was seen in 53.2 and 43.5% of the CRM-positive and CRM-nega-
tive group, respectively. CRM involvement was an independent prognostic factor 
for 5-year systemic recurrence-free survival (HR: 1.5, CI: 1.0-2.2, p=0.017). How-
ever, no significant difference was observed for local recurrence rate between the 
two groups (13.0 and 13.5%, respectively, p=0.677). Conclusion: In this study, lo-
cal recurrence rate did not differ according to CRM involvement status in stage III 
rectal cancer patients, although CRM involvement was shown to be an indepen-
dent poor prognostic factor. Accordingly, validation of the results of this study by 
further large prospective randomized trials is warranted.
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INTRODUCTION
After radical resection of rectal carcinoma, local recurrence (LR) remains a major 
problem, ranging in occurrence between 7.6 and 11.3%.1,2 With the introduction of 
novel treatment modalities such as total mesorectal excision and neoadjuvant 
chemoradiotherapy, the rate of local recurrence in rectal cancer has decreased sig-
nificantly.3-5
Circumferential resection margin (CRM) in rectal cancer has been defined as the 
non-peritonealized surface of a resection specimen created by dissection of the 
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from the aorta at its root. During surgery, care was taken to 
preserve the hypogastric nerve. The inferior mesenteric 
vein was ligated at the lower border of the pancreas. A 
sharp pelvic dissection was performed from the entrance to 
the pelvic cavity down to the pelvic floor, or the anal hiatus 
within the levator ani muscles along the visceral mesorectal 
fascia.15 Tumor-specific mesorectal excisions were per-
formed according to the tumor distance from the anal verge. 
For cases of upper rectal cancer, the mesorectum was ex-
cised 4 cm from the lower edge of the tumor. Total mesorec-
tal excision was performed for cases of mid and low rectal 
cancer at the level of the levator ani muscle.16 A potentially 
curative procedure was defined as one in which the surgeon 
believed that the entire tumor had been removed at the time 
of surgery. All of the patients registered in the prospectively 
collected colorectal database in our hospital made postoper-
ative follow-up visits every 2-3 months for 3 years. After 3 
years, follow-up visits were reduced to every 6 months un-
til 5 years, and annually thereafter. A physical examination, 
serum carcinoembryonic antigen (CEA) level measure-
ment, and chest radiography were performed at each fol-
low-up visit. Abdominopelvic CT scans and bone scintigra-
phies were performed annually. Chest CT, pelvic MRI, or 
18-FDG PET scan was performed as indicated according to 
the clinician’s decision. Patient follow-up lasted until the 
cutoff date (October 31, 2010), or when the patient died. 
The median follow-up period for all the patients was 56.6 
months (range, 4.9-230.9 months). 
Pathologic examination
Lymph nodes were retrieved after gross examination and 
manual palpation. All dissected and retrieved lymph nodes 
were stained with hematoxylin and eosin (H&E), and ex-
amined by light microscopy for the presence of tumor me-
tastasis. After confirming their proper orientation, surgical 
specimens were thoroughly inspected during gross exami-
nation. CRM was then identified as described by Quirke, et 
al.9 In some cases, the CRMs of the freshly received speci-
mens were stained using the Davidson Marking System 
(Bradley Product, Inc., Bloomington, MN, USA) and sub-
sequently fixed for 48 h. Dissection consisted of slicing 5 
mm serial sections of the whole tumor and the surrounding 
mesorectum in the transverse plane. Using a pathology 
slide (H&E stain), the shortest distance was measured from 
the microscopically lateral portion of the tumor to the stained 
CRM.11 CRM involvement was defined as a distance from 
the circumference margin of  ≤1 mm.9 Patients were divided 
subperitoneal aspect at surgery.6 CRM involvement occurs 
at a rate ranging from 7.3 to 25%.6-8 Many studies have 
demonstrated that CRM involvement is able to predict local 
recurrence and poor prognosis in patients with rectal can-
cer.7-11 For this reason, CRM positivity had been regarded 
as an important short-term end-point in well-designed clini-
cal trial for rectal cancer.12 In contrast, some previous inves-
tigators reported that CRM involvement showed no corre-
lation with local recurrence or long-term prognosis.13,14 
These results were based upon curatively operated patients 
with rectal cancer of several stages treated with or without 
neoadjuvant chemoradiotherapy. However, studies focusing 
on the prognostic impact of CRM involvement, especially 
in stage III rectal cancer patients treated with curative re-
section followed by adjuvant chemoradiotherapy, are rarely 
reported.
The aim of this study was to evaluate whether CRM in-
volvement could be a clinical parameter for predicting local 
recurrence or long-term prognosis in stage III rectal cancer 
patients. 
MATERIALS AND METHODS
　　　
Patient eligibility
Between January 1, 1990 and December 31, 2007, a total of 
811 patients diagnosed with stage III adenocarcinoma of the 
rectum within 12 cm from the anal verge after undergoing 
curative resection followed by selective adjuvant chemora-
diotherapy were extracted from our prospectively collected 
database. Of the 811 patients, due to patient refusal, poor 
performance status, or other reasons, only 525 patients com-
pleted the scheduled adjuvant chemoradiotherapy. Among 
the 525 patients, 76 in whom CRM was not measured were 
also excluded. The remaining 449 patients were eligible for 
this study.
Surgery and follow-up
Patients were staged via either a combination of appropriate 
imaging studies such as chest radiography, transrectal ultra-
sonography, pelvic magnetic resonance imaging (MRI), ab-
dominopelvic computed tomography (CT), or 18-FDG pos-
itron emission tomography (PET) before the operation. 
Patients received mechanical bowel preparation with poly-
ethylene glycol solution the day before surgery. Prophylac-
tic antibiotics were administered at the induction of anes-
thesia. The inferior mesenteric artery was doubly ligated 
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Statistical analysis
All statistical analyses were performed using SPSS soft-
ware, version 18.0 (SPSS, Chicago, IL, USA). Categorical 
variables were analyzed using the chi-square test or Fish-
er’s exact test, and continuous variables were analyzed us-
ing Student’s t-test. Local recurrence-free survival was de-
fined from the date of surgery to the date of detection of 
local recurrence. Systemic recurrence-free survival was de-
fined as the date of surgery to the date of detection of sys-
temic recurrence. Differences in survival and recurrences 
between the groups were compared using the Kaplan-Mei-
er method and tested with the log-rank test. Factors associ-
ated with local-recurrence free survival and systemic-recur-
rence free survival were analyzed by a Cox proportional 
hazards model done by a backward stepwise selection of 
variables. p-values <0.05 were considered statistically sig-
nificant. 
 
RESULTS
 
Patient characteristics
Of the 449 patients, 79 (17.6%) were classified as CRM-
positive group and 370 patients (82.4%) as CRM-negative 
group. The clinicopathological characteristics of the pa-
tients are summarized in Table 1. There were significant 
differences in CRM status according to the degree of lym-
phovascular invasion, tumor size, pathologic T stage, and 
pathologic N stage.
Local recurrence (LR) and systemic recurrence (SR)
Overall, 203 patients (45.2%) exhibited recurrence during 
the study period. Of these patients, 42 patients (20.7%) 
into two groups: ‘‘CRM-positive group’’ (CRM ≤1 mm) and 
‘‘CRM-negative group’’ (CRM >1 mm) according to the 
shortest distance between the CRM and the tumor (Fig. 1). 
Adjuvant chemoradiotherapy
In this study, 5-FU (450 mg/m2 for 5 days) and leucovorin 
(20 mg/m2 for 5 days) was given intravenously each month 
with six cycles. A total dose of 5040 cGY of external beam 
radiation therapy was delivered after the second round of 
chemotherapy (as supplied by a 6 MV/10 MV dual photon 
linear accelerator, CLINAC 2100 C, Varian, Palo Alto, CA, 
USA) in 30 fractions of 180 cGY each, five times weekly 
to the pelvic cavity with individually shaped portals and us-
ing a four-field box technique.17
Definition of recurrence
LR was defined as any recurrent tumor growth within the 
pelvic cavity or perineal area confirmed by clinical, radio-
logical or pathological evidence. For histological confirma-
tion, an imaging-guided biopsy was performed, when pos-
sible. Overall local recurrence rates were calculated as the 
sum of isolated LR and LR with concomitant systemic me-
tastases.8 Systemic recurrence was defined as recurrence 
outside the pelvis.
Lymph node ratio evaluation
Lymph node ratio (LNR) was defined as the ratio of meta-
static lymph nodes to total retrieved lymph nodes. Patients 
were categorized into three groups based on their LNR: 
Group 1=0<LNR≤0.099 (LNRG1); Group 2=0.01≤LNR 
≤0.249 (LNRG2); or Group 3=0.25≤LNR≤1.0 (LNRG3). 
This cut-off value was chosen based on the tertile number 
of LNR in this study group. 
Fig. 1. Pathologic findings of the CRM-positive and CRM-negative groups. The distance between the tumor and the circumferential resec-
tion margin was 1 mm (H&E staining, ×12) in the CRM-positive group (A), and 4 mm (H&E staining, ×12) in the CRM-negative group (B). 
CRM, circumferential resection margin.
A B
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nomatosis were significantly higher in the CRM-positive 
group than in the CRM-negative group (25.3% vs. 10.8%; 
p=0.001, and 6.3% vs. 1.9%; p=0.043, respectively) (Table 3). 
Survival analysis
The 5-year overall survival rate was 54.2% in the CRM-
were CRM positive and the remaining 161 patients (79.3%) 
were CRM negative. Isolated SR rate was higher in the 
CRM-positive group than that of the CRM-negative group, 
although the p-value thereof was only marginally signifi-
cant (40.5% vs. 29.7%, p=0.062) (Table 2). 
Among various patterns of SR, liver metastasis and carci-
Table 1. Clinicopathological Characteristics of Stage III Rectal Cancer Patients According to CRM Involvement Status
Variables
CRM ≤1 mm (n=79)
n (%)
CRM >1 mm (n=370)
n (%)
p value
Gender Male 46 (58.2) 232 (62.7) 0.457
Female 33 (41.2) 138 (37.3)
Age (yrs) <60 50 (63.3) 233 (63.0) 0.958
≥60 29 (36.7) 137 (37.0)
BMI (kg/m2) <25 54 (68.4) 257 (69.5) 0.619
≥25 16 (20.3)   83 (22.4)
No data   9 (11.4) 30 (8.1)
Histologic grade* G1 and G2 63 (79.7) 320 (86.5) 0.125
G3 and Etc. 16 (20.3)   50 (13.5)
LVI Negative 38 (48.1) 258 (69.7) <0.001
Positive 41 (51.9) 112 (30.3)
CEA (ng/mL) <5 49 (62.0) 232 (62.7) 0.910
≥5 30 (38.0) 138 (37.3)
Tumor size (cm) <5 39 (49.4) 242 (65.4) 0.007
≥5 40 (50.6) 128 (34.6)
Tumor location 7-12 cm 46 (58.2) 195 (52.7) 0.371
1-6 cm 33 (41.8) 175 (47.3)
pT T1 and T2 1 (1.3)   52 (14.1) 0.001
T3 and T4 78 (98.7) 318 (85.9)
pN N1 34 (43.0) 219 (59.2) 0.009
N2 45 (57.0) 151 (40.8)
LNR group LNRG1 (0-0.099) 22 (27.8) 132 (35.7) 0.270
LNRG2 (0.1-0.249) 25 (31.6) 120 (32.4)
LNRG3 (0.25-1.0) 32 (40.5) 118 (31.9)
Operation method APR 18 (22.8) 106 (28.6) 0.362†
Hartmann 4 (5.1) 11 (3.0)
SPP 57 (72.2) 253 (68.4)
Operation type Open surgery 75 (94.9) 350 (94.6) 1.0†
Lapa or robot surgery 4 (5.1) 20 (5.4)
BMI, Body Mass Index; LVI, lymphovascular invasion; CEA, carcinoembryonic antigen; CRM, circumferential resection margin; LNR, lymph node ratio; APR, 
abdominoperineal resection; SPP, sphincter preserving procedure. 
*Histologic grade; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; Etc., mucinous carcinoma and signet ring cell.
†Fisher’s exact test.
Table 2. Rate and Patterns of Recurrence According to CRM Involvement Status
CRM ≤1 mm (n=79) (%) CRM >1 mm (n=370) (%) p value
Local recurrence only 3 (3.8) 17 (4.6) 1.0*
Systemic recurrence only 32 (40.5) 110 (29.7) 0.062
Combined recurrence 7 (8.9) 34 (9.2) 0.927
Overall recurrence 42 (53.2) 161 (43.5) 0.118
CRM, circumferential resection margin.
Combined recurrence: local recurrence plus systemic recurrence.
*Fisher’s exact test.
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adjuvant chemoradiotherapy, CRM involvement proved to 
be an independent adverse prognostic factor. However, local 
recurrence rate did not differ between CRM-positive and 
CRM-negative patients.
The clinical relevance of CRM involvement in rectal can-
cer for oncological outcomes has been well documented 
since Quirke, et al.9 first reported the importance of CRM on 
prognosis. It was reported that CRM involvement increased 
the risks of both local recurrence and distant metastases.7-10 In 
contrast, Hall, et al.13 reported that although circumferential 
margin positive was associated with poor prognosis in terms 
of distant metastasis and survival in rectal cancer, CRM in-
volvement did not greatly increase the local recurrence rate 
due to the early development of distant disease rather than lo-
cal failure. Khani, et al.14 reported that there were no signifi-
cant differences in local recurrence and survival between 
CRM positive and negative tumors after preoperative radio-
therapy and postoperative chemotherapy. These previous 
studies included all stages of rectal cancer patients with or 
without preoperative chemoradiotherapy. In contrast, this 
study included a relatively large number of stage III rectal 
cancer patients in whom no preoperative chemoradiothera-
py had been applied. Therein, a strong positive association 
was observed for CRM involvement with distant recur-
positive group and 66.1% in the CRM-negative group. On 
univariate analysis, LNR group and pathologic N stage were 
shown to be significant predictors of LR, while lymphovas-
cular invasion, circumferential resection margin involve-
ment, LNR group, pathologic T stage, and pathologic N 
stage were shown to be significant predictors of SR (Table 
4). Cox proportional hazards analysis showed that LNR 
group was an independently predictor of LR. Additionally, 
preoperative CEA level, CRM involvement, pathologic N 
stage, and LNR group were shown to be independent pre-
dictors of SR on multivariate analysis (Table 5).
The cumulative incidences of LR and SR according to 
CRM status are shown in Fig. 2. The overall local recur-
rence rate (the sum of isolated LR and LR with concomi-
tant distant metastases) was not different regardless of 
whether the patient was CRM positive or not (5-year LR 
rate in the CRM-positive group 13.0% vs. CRM-negative 
group 13.5%; p=0.677).
DISCUSSION
In this study focusing on stage III rectal cancer patients who 
were treated with curative resection followed by complete 
Table 3. Site of Local and Systemic Recurrence according to CRM Involvement Status
CRM ≤1 mm (n=79) (%) CRM >1 mm (n=370) (%) p value
Overall systemic recurrence†
    Liver 20 (25.3) 40 (10.8) 0.001
    Lung 11 (13.9) 60 (16.2) 0.612
    Bone 1 (1.3) 19 (5.1) 0.224*
    Brain 1 (1.3) 3 (0.8) 0.540*
    Carcinomatosis 5 (6.3) 7 (1.9) 0.043*
    Inguinal lymph nodes 0 (0) 2 (0.5) 1.0*
    Etc. 2 (2.5) 13 (3.5) 1.0*
    Total 39 (49.4) 144 (38.9) 0.086
Overall local recurrence‡ 0.520
    Perineal 0 (0) 3 (0.8) 1.0*
    Pelvic 4 (5.1) 21 (5.7) 1.0*
    Anastomotic 2 (2.5) 12 (3.2) 1.0*
    Presacral 0 (0) 4 (1.1) 1.0*
    Vaginal 1 (1.3) 1 (0.3) 0.321*
    Bladder 1 (1.3) 2 (0.5) 0.441*
    Peritoneal 1 (1.3) 2 (0.5) 0.441*
    Etc. 1 (1.3) 7 (1.9) 1.0*
    Total 10 (12.7) 51 (13.8) 0.791
CRM, circumferential resection margin.
*Fisher’s exact test.
†Overall systemic recurrence (SR) is given as the sum of isolated SR and SR with concomitant local recurrence.
‡Overall local recurrence (LR) is given as the sum of isolated LR and LR with concomitant systemic recurrence.
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ther evidence to the report of Hall, et al.13 In our study, the 
median time to diagnosis of systemic recurrence from the 
rence. However, local recurrence rate was not correlated 
with CRM involvement status. This result might give fur-
Table 4. Univariate Analysis of Factors Associated with 5-Year Local Recurrence and 5-Year Systemic Recurrence
Variables 5-yr LR rate (%) p value 5-yr SR rate (%) p value
Gender Male 14.4 0.543 38.5 0.546
Female 12.1 40.2
Age (yrs) <60 14.4 0.220 35.5 0.059
≥60 11.9 45.4
BMI (kg/m2) <25 13.9 0.729 37.0 0.238
≥25 10.7 41.0
Unknown 17.9 50.6
Histologic grade* G1 and G2 13.3 0.791 36.9 0.104
G3 and Etc. 14.7 49.9
LVI Negative 12.4 0.549 34.1 0.001
Positive 16.2 49.0
CEA (ng/mL) <5 11.5 0.120 34.0 0.120
≥5 16.9 47.6
Tumor size (cm) <5 12.2 0.159 39.3 0.843
≥5 15.8 38.6
Tumor location 7-12 cm 11.5 0.236 36.2 0.230
1-6 cm 15.8 42.2
CRM Negative 13.5 0.677 37.1 0.008
Positive 13.0 48.9
LNR group LNRG1 (0-0.099)   6.2 0.014 17.9 <0.001
LNRG2 (0.1-0.249) 15.3 37.5
LNRG3 (0.25-1.0) 21.1 63.4
pT T1 and T2   8.6 0.265 22.0 0.009
T3 and T4 14.2 41.4
pN N1   8.7 0.004 25.1 <0.001
N2 20.6 57.6
Operation method APR or Hartmann procedure 17.1 0.166 45.8 0.168
SPP 11.9 36.4
LR, local recurrence; SR, systemic recurrence; BMI, body mass index; LVI, lymphovascular invasion; CEA, carcinoembryonic antigen; CRM, circumferential 
resection margin; LNR, lymph node ratio; APR, abdominoperineal resection; SPP, sphincter preserving procedure.
*Histologic grade; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; Etc., mucinous carcinoma and signet ring cell.
Table 5. Multivariate Analysis of Factors Associated with 5-Year Local Recurrence and 5-Year Systemic Recurrence
Variables
5-yr LR rate 
HR (95% CI)
p value
5-yr SR rate
HR (95% CI)
p value
CEA (ng/mL) <5 1
≥5 1.4 (1.0-1.8) 0.021
CRM Negative 1
Positive 1.4 (1.0-2.1) 0.033
pN N1 1
N2 1.5 (1.0-2.2) 0.032
LNR group LNRG1 (0-0.099) 1  1
LNRG2 (0.1-0.249) 2.2 (1.1-4.3) 0.022 1.6 (1.0-2.6) 0.042
LNRG3 (0.25-1.0) 2.5 (1.3-5.0) 0.006 3.1 (1.9-5.2) <0.001
LR, local recurrence; SR, systemic recurrence; CEA, carcinoembryonic antigen; CRM, circumferential resection margin; LNR, lymph node ratio; HR, hazard 
ratio; CI, confidence interval. 
Factors with a p-value of less than 0.20 on univariate analysis were entered into the multivariate analysis.
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recurrence-free and systemic recurrence-free survival. 
Neoadjuvant chemoradiotherapy (NCRT) could further 
lower the local recurrence rates compared with adjuvant 
chemoradiotherapy in rectal cancer.5 Clinical stages of T3 
or T4 and/or node positivity was regarded as a good candi-
date for NCRT. Due to enhancing diagnostic accuracy, es-
pecially in pelvic MRI, preoperative threatened or involved 
CRM was also regarded as an essential indication for NCRT 
to reduce CRM positive rates.19,20 According to our obser-
vations of a positive relationship between systemic recur-
rence and CRM involvement, threatened or involved CRM 
groups defined by preoperative MRI should be regarded as 
an immediate candidate for more urgent and intensified 
neoadjuvant chemotherapy in clinical trials. Accordingly, 
further prospective studies are warranted. 
In conclusion, in patients with stage III rectal cancer treat-
ed with curative resection followed by adjuvant chemora-
diotherapy, although CRM involvement was an important 
adverse prognostic factor, local recurrence rate was not cor-
related with CRM involvement status. For this reason, CRM 
involvement should be considered as an indicator of more 
advanced disease. Additionally, these features should be 
considered in establishing end-points in further randomized 
controlled trials for rectal cancer.
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primary resection in the CRM-positive group was shorter 
than that of the CRM-negative group (13.3 vs. 19.7 
months; p=0.052) (data not shown). This result might have 
originated from the more aggressive tumor biology in the 
CRM-positive group than in the CRM-negative group. For 
this reason, the rate of local recurrence could have appeared 
lower than it really was in the CRM-positive group.
It is known that low rectal cancers entails a higher posi-
tive CRM rate than upper rectal cancer.8 In the present 
study, the CRM positive rate in upper rectal cancer was 
higher than that of low rectal cancer, although this differ-
ence was not statistically significant. The reason for this 
phenomenon is difficult to explain. During the early periods 
of this study, abdominoperineal resection (APR) was fre-
quently performed for low rectal cancer. In this data set, the 
CRM positivity rate was 14.5% for patients who underwent 
APR and 18.4% for patients who underwent a sphincter-
preserving procedure (p=0.335, data not shown). From 
these data, we deduced that APR had been with excellently 
performed in our center, which could have lowered the 
CRM involvement rate in low rectal cancer. 
With regard to local recurrence-free survival, LNR re-
tained its significance in the multivariate analysis. With re-
gard to systemic recurrence-free survival, preoperative CEA 
level, LNR, pathologic N stage, and CRM retained their 
statistical significance in the multivariate analysis. These 
results are on par with published data. Recently, LNR was 
reported as an effective parameter for predicting patient 
prognosis in node positive colorectal cancer, though debate 
still exist as to the ideal cut-off value.18 In our analysis, LNR 
also proved to be an independent prognostic factor of local 
Fig. 2. Five-year cumulative recurrence rate according to CRM status. (A) Five-year local recurrence rate in the CRM(-) group (13.5%) and CRM(+) group 
(13.0%) (p=0.677). (B) Five-year systemic recurrence rate in the CRM(-) group (37.1%) and CRM(+) group (48.9%) (p=0.008). CRM, circumferential resection 
margin.
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